Three such studies in young adult women with breast cancer demonstrated decreased rates of amenorrhea in those patients who received GnRH analogues [43,44,45]; three trials in young adult patients with breast cancer [46,47] and Hodgkin lymphoma [48] demonstrated no protection of ovarian reserve using GnRH analogues. This evidence concerns the gene GNRH1 and Hodgkins lymphoma.